Drug Profile
Research programme: immuno-oncology therapeutics - Mirata Biopharma
Alternative Names: Granzyme B compounds; MRT-101; MRT-201; MRT-301Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Clayton Foundation for Research
- Developer Mirata BioPharma
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Gastric cancer; Lung cancer; Malignant melanoma
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Breast-cancer in USA (Parenteral)
- 28 Jan 2022 No recent reports of development identified for research development in Gastric-cancer in USA (Parenteral)
- 28 Jan 2022 No recent reports of development identified for research development in Lung-cancer in USA (Parenteral)